Spotlight On... Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections; Oral wet AMD player raises $12M; Novel hep B candidate funded to tune of $3M; and more...

Israel's PolyPid just raised $22 million from new investor Shavit Capital and others in a bid to put its lead surgical drug reservoir candidate into Phase III. The candidate releases the antibiotic doxycycline hyclate over four weeks, and is intended for patients suffering from severe open tibia fractures who are at high risk of infection. More

> Tyrogenex has raised $12 million in support of its oral therapy for the eye condition wet AMD. More

> Chromis Therapeutics has raised $3 million in support of its Hep B candidate that targets covalently closed circular DNA. More

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.